The expression of VE-cadherin and clarification of the pathological mechanism of tumor cells on multiple myeloma

• Project/Area Number: 25860780
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Hematology
• Research Institution: Gunma University
• Principal Investigator: IRIUCHISHIMA HIRONO 群馬大学, 医学部附属病院, 医員 (10621576)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 多発性骨髄腫 / CD28 / CD56 / 薬剤耐性 / VE-cadherin

Outline of Final Research Achievements

It was unlikely that the expression of VE-cadherin in human multiple myeloma (MM) cells. Because it was not detected by flow cytometry analysis and immunohistochemistry of the bone marrow in patients with MM. In contrast, CD28, which is indicated the involvement with interleukin-8, it has been noted that another angiogenesis related gene, was highly expressed in patients with relapse and/or refractory MM. Furthermore, several MM cell lines showed bortezomib-resistance in CD28 positive fractions.